NASDAQ · ANL
Adlai Nortye Ltd.
$10.28+$0.08 (+0.78%)
Adlai Nortye Ltd.’s quoted price sits in the upper half of its reported 52-week range, 40.41% below the high.
Loading market information…
NASDAQ · GOVX · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
GeoVax Labs, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.72% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
GeoVax Labs, Inc.’s next earnings report is currently expected on Nov 12, 2026, with estimated earnings per share of -$1.09. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow GeoVax Labs, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
GeoVax Labs, Inc. is a biotechnology company in the clinical development phase, focused on creating innovative human vaccines and immunotherapies. The firm targets both infectious diseases and various cancer types, utilizing its proprietary modified vaccinia ankara (MVA) virus-like particle (VLP) vaccine platform. Its product pipeline includes several prophylactic vaccines aimed at preventing illnesses such as COVID-19, human immunodeficiency virus (HIV), Zika virus, malaria, and a range of hemorrhagic fevers like Ebola, Sudan, Marburg, and Lassa. Additionally, GeoVax is developing therapeutic vaccines designed to treat existing conditions, specifically HIV, chronic Hepatitis B infections, and solid tumor cancers. To support its research and development efforts, GeoVax Labs, Inc. has forged partnerships with notable organizations. These collaborators include the National Institute of Allergy and Infectious Diseases (part of the National Institutes of Health), the Centers for Disease Control and Prevention, the U.S. Department of Defense, Emory University, the University of Pittsburgh, and the Burnet Institute. Founded in 1988, GeoVax Labs, Inc. is headquartered in Smyrna, Georgia.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:43 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $1.62M-2.89% vs estimate |
| Q4 2024 | Mar 27, 2025 | -$7.50+62.03% vs estimate | $882.50K-70.25% vs estimate |
|---|
| Q3 2024 | Nov 12, 2024 | -$22.75-1,437.16% vs estimate | $2.79M+108.91% vs estimate |
|---|
THE ANALYST VIEW
7 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$10.28+$0.08 (+0.78%)
Adlai Nortye Ltd.’s quoted price sits in the upper half of its reported 52-week range, 40.41% below the high.
$3.54+$0.22 (+6.63%)
Tharimmune, Inc.’s quoted price sits in the lower half of its reported 52-week range, 61.01% below the high.
$20.80+$0.83 (+4.16%)
Apollomics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 26.48% below the high.
$2.02+$0.02 (+1.0%)
BioLineRx Ltd.’s quoted price sits in the lower half of its reported 52-week range, 48.86% below the high.
$8.72-$0.03 (-0.29%)
Moleculin Biotech, Inc.’s quoted price sits in the lower half of its reported 52-week range, 97.23% below the high.
$0.03-$0.00 (-9.41%)
Adaptimmune Therapeutics plc’s quoted price sits in the lower half of its reported 52-week range, 92.73% below the high.
$2.31-$0.17 (-6.85%)
SeaStar Medical Holding Corporation’s quoted price sits in the lower half of its reported 52-week range, 61.5% below the high.
$0.73-$0.08 (-10.09%)
Ainos, Inc.’s quoted price sits in the lower half of its reported 52-week range, 81.21% below the high.
